A new study in Advanced Science (October 12, 2026) shows what becomes possible when patients donate tumor tissue and researchers pair it with detailed clinical and genetic data. The same idea drives the Synovial Sarcoma Registry and Biorepository, and every patient who joins makes the next study possible. What the study found Over ten years, […]
Two Leaders, One Mission: Nathan Imperiale and Philip Leider on Synovial Sarcoma
Our Chairman of the Board of Directors, Nathan Imperiale, was recently invited by Philip Leider, President of the Board of the Sarcoma Alliance, to present about the Synovial Sarcoma Foundation in a live webinar hosted by the Sarcoma Alliance. The conversation covered the Foundation’s origin story, our active research programs, and the resources available to […]
Two New TCR-NK Cell Therapy Trials Now Recruiting for Synovial Sarcoma
Two clinical trials testing TCR-NK cell therapy for advanced synovial sarcoma are now recruiting patients, one in the United States and one in the United Kingdom. Both use donor-derived natural killer cells engineered to target proteins commonly found on synovial sarcoma tumors. What Is TCR-NK Cell Therapy? TCR-NK therapy works differently from the TCR-T cell […]
Synovial Sarcoma Foundation Launches Ambassador Program During Childhood Cancer Awareness Month
New program invites patients, survivors, caregivers, and families to turn lived experience into advocacy. [Philadelphia, PA], September 1, 2026: This Childhood Cancer Awareness Month, the Synovial Sarcoma Foundation (SSF) is inviting patients, survivors, caregivers, and supporters to take their advocacy further. SSF has officially launched its Ambassador Program, an ongoing initiative for anyone connected to […]
How Better T Cell Manufacturing Could Unlock the Next Wave of Synovial Sarcoma Therapies
A study published in Cytotherapy by Kayo Toishigawa, Kenta Magoori, Hiroyuki Sato, and colleagues at Hiroshima University, in collaboration with Repertoire Genesis Inc. and Kyoto University, presents a promising new method for producing genetically engineered T cells at industrial scale using a technique called Platinum TALEN. The research is built around NY-ESO-1, one of the […]
Why a Melanoma Vaccine Breakthrough Matters for Synovial Sarcoma
Merck and Moderna are making headlines after their personalized mRNA cancer vaccine entered Phase 3 clinical trials for melanoma. For most people, it is an exciting medical story. For the synovial sarcoma community, it is something more personal than that. What the Vaccine Is mRNA-4157, combined with Merck’s immunotherapy pembrolizumab, works by sequencing a patient’s […]
A New CAR-T Cell Approach for Synovial Sarcoma That Does Not Require HLA Matching
A new preclinical study published in Biomedicine and Pharmacotherapy by Tomohiro Miyazaki, Yudai Murayama, Naoki Oike, and colleagues from the Department of Pediatrics and Division of Orthopedic Surgery at Niigata University Graduate School of Medical and Dental Sciences, Japan, presents early but promising evidence for a CAR-T cell therapy designed for synovial sarcoma that does […]
World’s First MAGE-A4-Targeting TCR-NK Therapy Zelluna Doses First Patient in Clinical Trial
Zelluna ASA, a Norwegian biotech company pioneering allogeneic cell therapies for solid cancers, recently announced that the first patient has received the first dose of ZI-MA4-1 in the ZIMA-101 Phase 1 clinical trial. The treatment was administered at The Christie NHS Foundation Trust in Manchester, United Kingdom, the largest single-site cancer centre in Europe, marking […]
TECELRA Receives Full FDA Approval, Expands Access to Adolescents with Synovial Sarcoma
US WorldMeds® announced that the U.S. Food and Drug Administration has granted full approval to TECELRA® (afamitresgene autoleucel), with an expanded indication that now includes eligible patients as young as 12 years old. The therapy, which received its original accelerated approval in August 2024, remains the first and only FDA-approved engineered T-cell therapy for a […]
Synovial Sarcoma Foundation Announces Formation of Medical Advisory Board
11 Leading Oncologists and Researchers Unite to Accelerate Progress for Synovial Sarcoma Patients PHILADELPHIA [June 22, 2026] The Synovial Sarcoma Foundation (SSF) today announced the formation of its Medical Advisory Board, bringing together 11 internationally recognized clinicians and researchers to serve as the central coordinating body for synovial sarcoma research, treatment, and advocacy. The board […]










